Santarus Inc. (SNTS) on Monday received FDA approval for UCERIS for the induction of remission in patients with active, mild to moderate ulcerative colitis. The commercial launch of UCERIS is expected in March 2013.
With one more product added in its portfolio, the company expects 2013 revenue to range between $320 million and $325 million, representing significant double-digit growth over our 2012 revenue guidance.
VG Life Sciences (VGLS) rose over 5% to close Monday's trading at $0.37 following approval from the Institutional Review Board of the University of Texas Health Science Center San Antonio to expand the types of cancers being studied in the ongoing physician-initiated phase 1 clinical trial with MDT compound in combination with Nexavar.
Accordingly, apart from ovarian cancer, the study will also evaluate the treatment in the indications of breast, colon, lung, liver and pancreas cancers.
VG Life Sciences holds the exclusive worldwide license to the body of patents underlying the use of MDT compounds in the treatment of cancers.
Alnylam Pharmaceuticals Inc. (ALNY) on Monday announced it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $125 million.
The stock closed Monday's trading 1.93% higher at $20.55.
InterMune Inc. (ITMN) was down 4.9% to $9.50 in after-hours trading on Monday after the company announced its plan to offer $85.0 million aggregate principal amount of convertible senior notes due 2017 and 12.5 million shares of its common stock in concurrent underwritten public offerings.
ScripsAmerica Inc. (SCRC), on Monday entered into an Investment Banking Consulting Agreement with Implex Corp. Under the agreement, which has an initial term of six months, Implex will provide ScripsAmerica with corporate, business and investment banking services, including the analysis and the rendering of advice on the company's current corporate and financial structures as well as its need for capitalization.
The stock closed Monday's trading at $0.33, up 7.87%.
BioRestorative Therapies Inc. (BRTX) will be presenting its research on "Human Metabolically Active Brown Adipose Tissue Derived Stem Cells" at the Adipose Tissue Biology conference of the Keystone Symposia conference series on January 30, 2013.
The company is focused on developing medical procedures using cell and tissue protocols, primarily involving adult stem cells (non-embryonic), and allowing patients to undergo minimally invasive cellular-based treatments.
The stock closed Monday's trading at $0.02, down 12.5%.
PharmAthene Inc. (PIP) on Monday announced it has secured an exclusive license for the use of Percivia LLC's proprietary PER.C6 technology platform for commercial production of recombinant bioscavenger.
Percivia is a joint venture formed by Royal DSM N.V., the global Life Sciences and Materials Sciences company, and Dutch biopharmaceutical company Crucell N.V., both headquartered in the Netherlands.
PharmAthene noted that if successful, its rBChE bioscavenger platform could provide an efficient and flexible manufacturing approach and a more cost-effective solution for the U.S. government to protect the U.S. military and citizens from chemical weapons.
BSD Medical Corp. (BSDM) on Monday announced it has sold multiple MicroThermX Microwave Ablation systems and antennas to ADA Medikal, a medical, specialty distributor in Turkey under an exclusive distribution agreement that was signed last October.
The stock closed Monday's trading 5.54% higher at $1.65.
Bristol-Myers Squibb Co.'s (BMY) anticancer drug ERBITUX in combination with chemotherapy has been approved in Canada as initial treatment of patients with metastatic colorectal cancer.
Erbitux was initially approved in Canada in 2008 for the treatment of epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer for patients whose disease progressed after chemotherapy.
OPKO Health Inc. (OPK) touched a new high of $5.78 on Monday before closing the day's trading at $5.71 following the company's expanded collaboration with Bristol-Myers Squibb Co. (BMY).
OPKO entered into a multi-year collaboration agreement with Bristol-Myers Squibb in 2010 to investigate the utility of OPKO's novel technology for the diagnosis of Alzheimer's disease and for identifying individuals with early stage cognitive impairment that are likely to progress to Alzheimer's disease.
The expanded collaboration will allow the Alzheimer's project and additional investigations to use OPKO's technology in an attempt to identify biomarkers that are predictive of drug response(s) in several therapeutic areas.
Neuralstem Inc. (CUR) rose 4.03% on Monday to close at $1.29 following FDA clearance to commence a phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients.
The study is designed to enroll up to eight patients with thoracic spinal cord injuries and they will receive six injections in, or around, the injury site. The trial study period will end six months post-surgery for each patient.
La Jolla Pharmaceutical Co. (LJPC.OB) announced Monday that it recently appointed Stacey Ruiz, as Director of Research and Development, and Chester Zygmont III as Director of Finance.
The stock closed Monday's trading 14.86% higher at $0.08.
PURE Bioscience Inc. (PURE) says that its Hard Surface disinfectant provides rapid 30-second kill against a wide range of viruses, including the dangerous influenza virus.
PURE closed Monday's trading at $0.98, up 7.69%.
Covidien plc (COV) on Monday opened enrollment in a new study, dubbed SWIFT PRIME, to examine the adjunctive use of mechanical thrombectomy during the early stages of acute ischemic stroke onset. The study that will use Solitaire FR device aims to better understand the patient population that most benefits from thrombolysis combined with mechanical thrombectomy.
The SWIFT PRIME trial is designed to enroll up to 800 patients across 60 centers globally.
Theratechnologies Inc. (TH.TO) (THER) announced it is all set to seek a voluntary delisting from the NASDAQ Global Market. The company hasn't regained compliance with the minimum bid price requirement with the deadline looming on February 4, 2013.
It is expected that delisting from the NASDAQ will take effect as of the close of trading on February 4, 2013. However, the company's common shares will continue trading on the Toronto Stock Exchange under the symbol "TH".
SciClone Pharmaceuticals Inc. (SCLN) on Monday announced the appointment of Simon Li to its board of directors. Most recently, Li served as the Global Officer and Member of the Executive Committee of Medtronic, and also held the positions of President, Greater China and Chairman of the Board, Medtronic-Weigao JV.
by RTT Staff Writer
For comments and feedback: email@example.com